Endothelial Interactions and Coagulation

  • Trung C. Nguyen
  • Joseph A. Carcillo


Circulating blood is the lifeline of our existence, transporting oxygen, glucose and other substrates for energy production. The circulatory system supplies complements, platelets, and white blood cells to combat infections and repair tissues, as well as platelets and soluble coagulation and anti-coagulation proteins and proteases, to prevent uncontrolled bleeding and clotting. The coordination of these vital functions is orchestrated by a thin layer of cells named the endothelium. Endothelial cells direct blood flow by differentially expressing vasoconstrictors (e.g. endothelin, 20-HETE) and vasodilators (e.g. nitric oxide, prostacyclin). These cells direct white blood cell trafficking by differentially expressing the adhesion molecules endothelium selectin (E-selectin), inter-cellular adhesion molecule (ICAM), and vascular cell adhesion molecule (VCAM). Finally, the endothelium directs clotting by differentially releasing ultra-large von Willebrand factor multimers (initiating platelet aggregation), decreasing thrombomodulin (preventing anticoagulation) and increasing plasminogen-activator inhibitor type-1 (PAI-1) expression preventing fibrinolysis. This chapter focuses on the physiology and pathophysiology of the endothelium and the cellular and soluble coagulation system. The objective of this chapter is to prepare the pediatric intensivist to choose specific and non-specific therapies for critically ill children with thrombotic and/or bleeding disorders.


Plasma Exchange Disseminate Intravascular Coagulation Thrombotic Thrombocytopenic Purpura Tissue Factor Pathway Inhibitor Thrombotic Microangiopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Bell W, Braine H, Ness P, Kickler T. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. N Engl J Med. 1991;325:398–403.PubMedCrossRefGoogle Scholar
  2. Bernard GR, Vincent JL, Laterre PF, LaRosa JP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699–709.PubMedCrossRefGoogle Scholar
  3. Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment and assessment of therapeutic response. Semin Thromb Hemost. 1996;22:69.PubMedCrossRefGoogle Scholar
  4. Bick RL. Disseminated intravascular coagulation: pathophysiologic mechanisms and manifestations. Semin Thromb Hemost. 1998;24:3.PubMedCrossRefGoogle Scholar
  5. Bongers TN, Emonts M, de Maat MP, de Groot R, Lisman T, Hazelzet JA, et al. Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. Thromb Haemost. 2010;103(6):1181–7.PubMedCrossRefGoogle Scholar
  6. Bridges DJ, Bunn J, van Mourik JA, Grau G, Preston RJ, Molyneux M, et al. Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. Blood. 2010;115(7):1472–4.PubMedCrossRefGoogle Scholar
  7. Brilliant SE, Lester PA, Ohno AK, Carlon MJ, Davis BJ, Cusher HM. Hemolytic uremic syndrome without evidence of microangiopathic hemolysis on peripheral blood smear. South Med J. 1996;89(3):342–5.PubMedCrossRefGoogle Scholar
  8. Busund R, Koukline V, Utrobin U, Nedashovsky E. Plasmapheresis insevere sepsis and septic shock: a prospective randomized controlled trial. Intensive Care Med. 2002;28(10):1434–9.PubMedCrossRefGoogle Scholar
  9. Churchwell KB, McManus ML, Kent P, Gorlin J, Galacki D, Humphreys D, et al. Intensive blood and plasma exchange for treatment of coagulopathy in meningococcemia. J Clin Apher. 1995;10(4):171–7.PubMedCrossRefGoogle Scholar
  10. Dreyfus M, Masterson M, David M, Rivard GE, Muller FM, Kreuz W, et al. Replacement therapy with a monoclonal Ab purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost. 1995;21(4):371–81.PubMedCrossRefGoogle Scholar
  11. Fava S, Galizia AC. Thrombotic thrombocytopenic purpura-like syndrome in the absence of schistocytes. Br J Haematol. 1995;89(3):643–4.PubMedCrossRefGoogle Scholar
  12. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double blind placebo controlled trial of antithrombin III concentrate in septic shock with disseminated intravascular coagulation. Chest. 1993;104(3):882–8.PubMedCrossRefGoogle Scholar
  13. Green J, Doughty L, Kaplan SS, Sasser H, Carcillo JA: The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. Thromb Haemost 2002, 87(2):218–223.PubMedGoogle Scholar
  14. Gross SM, Kennan JJ. Whole blood transfusion for exsanguinating coagulaopathy in a US field surgical hospital in Kosovo. J Trauma. 2000;49(1):145–8.CrossRefGoogle Scholar
  15. Harrison CN, Lawrie AS, Iqbal A, Hunter A, Machin SJ. Plasma exchange with solvent/detergent treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol. 1996;94(4):756–8.PubMedCrossRefGoogle Scholar
  16. Hattersley PG, Kuntel M. Cryoprecipitate as a source of fibrinogen in treatment of disseminated intravascular coagulation. Transfusion. 1976;16(6):641–5.PubMedCrossRefGoogle Scholar
  17. Hermans PW, Hillerd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, et al. 4 G/5G promoter polymorphism in the plasminogen activator inhibitor 1 gene and outcome of meningococcal disease. Meningococcal Disease Group. Lancet. 1999;354(9178):556–60.PubMedCrossRefGoogle Scholar
  18. Kwan HC. Thrombotic microangiopathy. Semin Hematol. 1987a;24(2):69–81.Google Scholar
  19. Kwan HC. Miscellaneous secondary thrombotic microangiopathy. Semin Hematol. 1987b;24(3):141–7.Google Scholar
  20. Leclerc F, Hazelzet JA, Jude B, Hofhuis W, Hue V, Martinot A, et al. Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med. 1991;18:202–5.CrossRefGoogle Scholar
  21. Lowenberg EC, Charunwatthana P, Cohen S, van den Born BJ, Meijers JC, Yunus EB, et al. Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thromb Haemost. 2010;103(1):181–7.PubMedCrossRefGoogle Scholar
  22. McManus ML, Churchwell KD. Coagulopathy as a predictor of outcome in meningococcal sepsis and systemic inflammatory response syndrome with purpura. Crit Care Med. 1993;21(5):706–11.PubMedCrossRefGoogle Scholar
  23. Nguyen T, Hall Y, Fiedor M, Hasset A, Lopez-Plena I, Watson S, et al. Microvascular thrombosis in pediatric multiple organ failure: is it a therapeutic target? Pediatr Crit Care Med. 2001;21(5):187–96.CrossRefGoogle Scholar
  24. Nguyen TC, Liu A, Liu L, Ball C, Choi H, May WS, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haemato­logica. 2007;92(1):121–4.PubMedCrossRefGoogle Scholar
  25. Nguyen TC, Han YY, Kiss JE, Hall MW, Hassett AC, Jaffe R, et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med. 2008;36(10):2878–87.PubMedCrossRefGoogle Scholar
  26. Park YD, Yoshioka A, Kawa K, Ishizashi H, Yagi H, Yamamoto Y, et al. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant. 2002;29(9):789–94.PubMedCrossRefGoogle Scholar
  27. Riewald M, Reiss H. Treatment options for clinically recognized disseminated intravacular coagulation. Semin Thromb Hemost. 1998;24(1):53–9.PubMedCrossRefGoogle Scholar
  28. Rintala E, Kauppila M, Seppala O, Voipio-Pulkk L, Pettila V, Rasi V, et al. Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med. 2000;28:2373–8.PubMedCrossRefGoogle Scholar
  29. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group [see comments]. N Engl J Med. 1991;325(6):393–7.PubMedCrossRefGoogle Scholar
  30. Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol. 1996;94(2):383–6.PubMedCrossRefGoogle Scholar
  31. Sagripanti A, Carpi A, Rosaia B, Morelli E, Innocenti M, D’Acunto G, et al. Iloprost in the treatment of thrombotic microangiopathy: report of thirteen cases. Biomed Pharmacother. 1996;50(8):350–6.PubMedCrossRefGoogle Scholar
  32. Weinstein MJ, Blanchard R, Moake JL, Vosburgh E, Moise K. Fetal and neonatal von Willebrand factor (VWF) is unusually large and similar to the VWF in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 1989;72(1):68–72.PubMedCrossRefGoogle Scholar
  33. Williams CK, Fernbach B, Cuttner J, Hallert JF, Essien ER. Management of leukemia associated disseminated intravascular coagulation. Haematologia. 1982;15(3):287–95.PubMedGoogle Scholar
  34. Zenz W, Bodo Z, Zobel G. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med. 2000;26(5):969–71.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  • Trung C. Nguyen
    • 1
  • Joseph A. Carcillo
    • 2
  1. 1.Pediatric Critical Care Medicine, Department of PediatricsBaylor College of Medicine, Texas Children’s HospitalHoustonUSA
  2. 2.Pediatric Critical Care Medicine, Department of Critical Care MedicineUniversity of Pittsburgh School of Medicine, Children’s Hospital of Pittsburgh of UPMCPittsburghUSA

Personalised recommendations